NCT05712642View on ClinicalTrials.gov

A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

January 28, 2021

Conditions
Retinopathy of Prematurity
Interventions
DRUG

Intravitreal Bevacizumab

Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab

Trial Locations (1)

11865

Faculty of Medicine Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT05712642 - A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity | Biotech Hunter | Biotech Hunter